Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
4,590.00    24.00 (0.53%)
Bid:
4,588.00
Ask:
4,592.00
Spread: 4.00 (0.087%)
Market Cap: £16.73b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Correction - Total voting rights

27 Jan 2025 15:13

RNS Number : 8344U
Coca-Cola HBC AG
27 January 2025
 

 

Coca-Cola HBC AG

Correction - Total voting rights

The following amendment has been made to the Total Voting Rights announcement (RNS no. 1134S) made at 11:51:00 on 3 January 2025.

The original announcement incorrectly stated that there had been a transfer of treasury shares in the month ended 31 December 2024. The correct figure to be used for the total number of treasury shares held by Coca-Cola HBC AG is 7,647,662 and the correct figure to be used for the total number of voting rights is 362,161,765. The full amended text is shown below.

Zug, Switzerland - 27 January 2025 - Coca-Cola HBC AG ("Coca-Cola HBC") announces in respect of the month ended 31 December 2024, Coca-Cola HBC's issued share capital consisted of 373,239,562 ordinary shares of CHF 6.70 each ("Ordinary Shares"), of which 7,647,662 Ordinary Shares are held by Coca-Cola HBC AG and 3,430,135 Ordinary Shares are held by its subsidiary, Coca-Cola HBC Services MEPE, in treasury. Accordingly, as of 31 December 2024, the total number of voting rights in Coca-Cola HBC is 362,161,765 for the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTRs").

Shareholders may use the above total voting rights figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of Coca-Cola HBC under the DTRs.

This announcement is made in accordance with DTR 5.6.1.

 

 

Enquiries 

Coca-Cola HBC Group 

Investor and Analysts: 

Joanna Kennedy 

Former Head of Investor Relations 

Tel: +44 7802 427505

 joanna.kennedy@cchellenic.com

Jemima Benstead 

Head of Investor Relations 

Tel: +44 7740 535130 

jemima.benstead@cchellenic.com 

Media: 

Sonia Bastian 

Head of Communications 

Tel: +41 7946 88054 

sonia.bastian@cchellenic.com 

Claire Evans

Group Senior Communications Manager - Corporate

 

Tel:+44 7597 562 978 

claire.evans@cchellenic.com

 

 

 

 

 

 

 

 About Coca-Cola HBC

 

Coca-Cola HBC is a growth-focused consumer packaged goods business and strategic bottling partner of The Coca-Cola Company. We open up moments that refresh us all, by creating value for our stakeholders and supporting the socio-economic development of the communities in which we operate. With a vision to be the leading 24/7 beverage partner, we offer drinks for all occasions around the clock and work together with our customers to serve 740 million consumers across a broad geographic footprint of 29 countries. Our portfolio is one of the strongest, broadest and most flexible in the beverage industry, with consumer-leading beverage brands in the sparkling, adult sparkling, juice, water, sport, energy, ready-to-drink tea, coffee, and premium spirits categories. These include Coca-Cola, Coca-Cola Zero Sugar, Fanta, Sprite, Schweppes, Kinley, Costa Coffee, Caffè Vergnano, Valser, FuzeTea, Powerade, Cappy, Monster Energy, Finlandia Vodka, The Macallan, Jack Daniel's and Grey Goose. We foster an open and inclusive work environment amongst our 33,000 employees and believe that building a more positive environmental impact is integral to our future growth. We rank among the top sustainability performers in ESG benchmarks such as the Dow Jones Sustainability Indices, CDP, MSCI ESG, FTSE4Good and ISS ESG.

Coca-Cola HBC is listed on the London Stock Exchange (LSE: CCH) and on the Athens Exchange (ATHEX: EEE). For more information, please visit https://www.coca-colahellenic.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREASFXAFASEFA
Date   Source Headline
27th Feb 20181:05 pmRNSDirector/PDMR Shareholding
26th Feb 20183:33 pmRNSDirector/PDMR Shareholding
23rd Feb 201810:53 amRNSDirector/PDMR Shareholding
22nd Feb 20184:28 pmRNSHolding(s) in Company
22nd Feb 20183:02 pmRNSDirector/PDMR Shareholding
21st Feb 201810:21 amRNSDirector/PDMR Shareholding
21st Feb 201810:13 amRNSDirector/PDMR Shareholding
20th Feb 20182:16 pmRNSDirector/PDMR Shareholding
20th Feb 20181:31 pmRNSDirector/PDMR Shareholding
20th Feb 20181:19 pmRNSDirector/PDMR Shareholding
20th Feb 20181:00 pmRNSDirector/PDMR Shareholding
16th Feb 201811:22 amRNSDirector/PDMR Shareholding
14th Feb 20187:00 amRNSEXCEPTIONAL SET OF RESULTS
1st Feb 201810:35 amRNSIssue of equity and total voting rights
19th Jan 20184:02 pmRNSDirector/PDMR Shareholding
17th Jan 201811:05 amRNSNotice of Results
5th Jan 20184:02 pmRNSAthens Exchange trading date of ordinary shares
2nd Jan 201810:04 amRNSIssue of equity and total voting rights
20th Dec 20172:15 pmRNSDirector/PDMR Shareholding
7th Dec 20177:00 amRNSAppointment of Chief Executive Officer
1st Dec 20179:06 amRNSIssue of Equity and Total Voting Rights
20th Nov 201711:57 amRNSDirector/PDMR Shareholding
9th Nov 20177:00 amRNSCONTINUING TO DELIVER EXCELLENT REVENUE GROWTH
1st Nov 20179:07 amRNSIssue of Equity and Total Voting Rights
1st Nov 20178:55 amRNSBlock listing Interim Review
18th Oct 201712:55 pmRNSDirector/PDMR Shareholding
9th Oct 201711:45 amRNSNotice of Results
3rd Oct 20177:00 amRNSStatement re. Chief Executive Officer
2nd Oct 20179:27 amRNSIssue of Equity and Total Voting Rights
27th Sep 201711:13 amRNSDirector Declaration
19th Sep 20173:30 pmRNSDirector/PDMR Shareholding
15th Sep 20177:01 amRNSCEO's medical leave of absence
1st Sep 20179:30 amRNSIssue of Equity and Total Voting Rights
21st Aug 201711:37 amRNSDirector/PDMR Shareholding
10th Aug 20177:00 amRNSEXCELLENT FIRST HALF RESULTS
1st Aug 20179:35 amRNSIssue of Equity and Total Voting Rights
28th Jul 20171:02 pmRNSDirector/PDMR Shareholding
19th Jul 20171:51 pmRNSDirector/PDMR Shareholding
4th Jul 201712:56 pmRNSNotice of Results
3rd Jul 20178:16 amRNSIssue of Equity and Total Voting Rights
21st Jun 20179:26 amRNSDirectorate Change
21st Jun 20179:15 amRNSResult of AGM
20th Jun 20173:00 pmRNSDirector/PDMR Shareholding
2nd Jun 201711:42 amRNSAthens Exchange trading date of ordinary shares
1st Jun 20177:54 amRNSIssue of Equity and Total Voting Rights
19th May 201712:24 pmRNSDirector/PDMR Shareholding
16th May 20177:11 amRNSNotice of AGM
15th May 20177:23 amRNSchange to the Board and confirms dividend dates
11th May 20177:00 amRNSYEAR STARTS WELL WITH GOOD REVENUE GROWTH
2nd May 20179:07 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.